Personalis Announces New Data to be Presented at AACR Virtual Scientific Meeting
These abstract showcases data from ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform® can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following are details and links to the scientific posters that will be presented at the online meeting.
Abstract Number, Session Category and Session Title |
Title & Presenter |
Date |
Location |
2085 / 2 Machine Learning |
Presenter: |
|
|
1989 / 26 Clinical Research Circulating Markers 2 |
Presenters: Mengyao Tan and |
|
|
1334 / 29 Molecular and Cellular Biology/Genetics Genomic Profiling of Tumors 2 |
Presenter: |
|
|
2512 / 28 Molecular and Cellular Biology/Genetics Genomic Profiling of Tumors 3 |
Presenter: |
|
|
4430 / 25 Tumor Heterogeneity and Microenvironment: Next-Generation Sequencing, Single Cell, and Imaging |
Quantification of tumor-infiltrating immune cell populations with an augmented transcriptome
Presenter: |
|
|
4278 / 2 Clinical Research Predictive Biomarkers for Treatment Efficacy 3
|
Presenter: |
|
|
6678 / 24 Immunology Immune Response to Therapies 2 |
Presenter: |
|
|
852 / 2 Machine Learning and Artificial Intelligence for |
Improved tumor-only somatic variant calling using a gradient boosted machine learning algorithm
Presenter: |
|
About
Forward-Looking Statements
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that are not historical facts, including, for example, statements regarding the future availability, features or potential uses of the ImmunoID NeXT Platform and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis’ filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005219/en/
Investor Relations Contact:
investors@personalis.com
415-202-5678
Media Contact:
pr@personalis.com
www.personalis.com
650-752-1300
Source: